Clinical trials: Cephalalgia
Migraine
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- NCT06692881
- Where
- 13 sites in Canada
- Volunteers
- 178 people
- Sponsor
- AbbVie
Migraine Headache
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.
- Trial name
- NCT00897949
- Testing
- rizatriptan benzoate (MK0462)
- Volunteers
- 1,473 people
- Sponsor
- Organon and Co
Migraine
A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache at the earliest onset of headache…
- Trial name
- NCT00210509
- Testing
- almotriptan malate
- Volunteers
- 378 people
- Sponsor
- Janssen-Ortho LLC
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
Migraine Disorders
American Migraine Prevention Study
The purpose of this study is to evaluate the use of nutritional supplementation and dietary management for the reduction in frequency, duration, and intensity of migraine headache pain.
- Trial name
- NCT00363506
- Testing
- Serotona Plus and dietary behavior management
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Dynamic Health Resources
Migraine Without Aura
Migraine STImulation Crisis of Migraine
Migraine is a neurovascular disease whose prevalence is estimated at almost 20% of the adult population. Currently, there is no treatment for migraine.
- Trial name
- MISTIC (NCT04568252)
- Testing
- Wristband with millimeter wave emission.
- Where
- 6 sites in France
- Volunteers
- 140 people
- Sponsor
- Remedee SA
Pregnancy, Migraine
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women.
- Conditions
- Pregnancy, Migraine, Headache, Postpartum
- Trial name
- NCT06788977
- Testing
- external Trigeminal Nerve Stimulation
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Cefaly Technology
Migraine Disorders
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment.
- Trial name
- NCT06154070
- Testing
- DaxibotulinumtoxinA
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ki Health Partners. LLC
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
- Trial name
- PROMISE 1 (NCT02559895)
- Testing
- ALD403
- Where
- 87 sites in United States, Georgia
- Volunteers
- 898 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Migraine
Real-World Evidence (RWE) Data Analysis of 1-year Consecutive Use of Remote Electrical Neuromodulation (REN)
This is a Post-marketing study investigating the long-term safety, utilization, and efficacy of REN during 12 consecutive months of using Nerivio in migraine patients.
- Trial name
- NCT05760638
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 409 people
- Sponsor
- Theranica
Migraine
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.
- Trial name
- NCT01613248
- Testing
- MK-1602, Rescue medication
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine Disorders, Headache Disorders, Primary
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
This trial is collaboration between Mayo Clinic, Second Opinion Health (Simon Bloch, simon@somobilehealth.com 408-981-3814) and Allergan.
- Conditions
- Migraine Disorders, Headache Disorders, Primary, Headache Disorders, Brain Diseases
- Trial name
- Migraine Alert (NCT02910921)
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Second Opinion Health
Migraine
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
This will be a randomized, single dose, double-blind, placebo-controlled, Latin-square design with 5-period (full) crossover study with participants randomized to treatment sequences. Participants will complete all 5 Periods.
- Trial name
- NCT03012334
- Testing
- Lasmiditan, Alprazolam
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Biomarker and Genetic Predictors of Erenumab Treatment Response
To explore the relationship between clinical response to erenumab and genetic biomarkers
- Trial name
- INTERROGATE (NCT04265755)
- Testing
- Erenumab
- Where
- 2 sites in Denmark, Iceland
- Volunteers
- 1,406 people
- Sponsor
- Amgen
Migraine
Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. There are 4 cohorts of 8 subjects (8 active and 2 placebo) planned for evaluation under fasting conditions.
- Trial name
- NCT04104399
- Testing
- XC101-D13H
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Xoc Pharmaceuticals
Migraine, Common Migraine
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg taken daily) compared with placebo in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00236509
- Testing
- topiramate
- Volunteers
- 763 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.